John Morris, MD Nephrology – BMH Memphis I have the following financial relationships with commercial interests to disclose: NONE Disclosure.

Slides:



Advertisements
Similar presentations
Learning objectives To understand the pathophysiologic basis for vasoactive therapies for HRS To become familiar with the diagnostic criteria for HRS To.
Advertisements

HEART FAILURE (HF) Heart failure is the pathophysiological state in which an abnormality of cardiac function is responsible for failure of the heart to.
Advance Heart Failure Therapy
Hemodynamic Disorders, Thrombosis & Shock
EVIDENCE IN THE ED AMOS SHEMESH, MD, PGY-III MARCH 2014 LMNOP in ADHF: Should Lasix Stay in the Acronym?
Horng H Chen MD on behalf of the NHLBI Heart Failure Clinical Research Network Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF):
Perioperative Management of Heart Failure Gamal Fouad S Zaki, MD Professor of Anesthesiology Ain Shams University
Congestive Heart Failure
 Heart failure is a complex clinical syndrome Can result from:  structural or functional cardiac disorder  impairs the ability of the ventricle to.
Neurohormonal Activation especially AVP in Congestive Heart Failure 陈宇寰 丁 宁 高 柳 郭华秋 韩国嵩 臧 鹏.
Heart Failure, Shock and Hemodynamics Howard Sacher D.O. Long Island Cardiology.
1 Cardiac Pathophysiology Part B. 2 Heart Failure The heart as a pump is insufficient to meet the metabolic requirements of tissues. Can be due to: –
Inpatient Management of Heart Failure Mini-Lecture.
Pharmacologic Treatment of Chronic Systolic Heart Failure John N. Hamaty D.O. FACC, FACOI.
The Macstrak Project ER Case Studies The following is a series of case studies to review different patient types and how they are captured on the form.
Biomarkers in the Cardiorenal Syndromes
Medical Progress: Heart Failure. Primary Targets of Treatment in Heart Failure. Treatment options for patients with heart failure affect the pathophysiological.
Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.
Nursing and heart failure
Management of Heart Failure Overview Interactive exercise What colour are your sunglasses? Update on pathophysiology of HF Interactive case study Heart.
Sept 25,  Pulmonary HTN is defined as mean pulmonary artery pressure of > 25 mm Hg (as seen on echo)  Causes of Pulmonary HTN include: PE, COPD,
Congestive Heart Failure Arun Abbi M.D.. Outline 1. Classification and epidemiology 2. Pathophysiology 3. Diagnosis 4. Treatment 5. Conclusions.
Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.
– Dr. J. Satish Kumar, MD, Department of Basic & Medical Sciences, AUST General Medicine CVS Name:________________________________________ Congestive Heart.
Cor Pulmonale Dr. Meg-angela Christi Amores. Definition Cor Pulmonale – pulmonary heart disease – dilation and hypertrophy of the right ventricle (RV)
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Angiotensin-Converting Enzyme Inhibitor–Associated.
Cardiorenal Syndrome Samira Tabiban MD Rajaie Cardiovascular medical and research center.
신장내과 R4 강혜란 Cardiorenal syndrome (CRS).  Patients with heart failure (HF) who have a reduced GFR -> Mortality ↑  Patients with chronic kidney disease.
بسم الله الرحمن الرحيم.
An AKI project for critically ill cancer patients
Pre-Clinical Models and Clinical Studies to
Liver Disease tutoring Part 1
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
Kidney Injury and Liver Disease in the ICU
Pharmacotherapy Of Cardiovascular Disorders: Heart Failure
Heart Failure NURS 241 Chapter 35 (p.797).
Heart and Circulatory Failure
Effects of Uric acid- lowering therapy on renal outcomes: a systematic review and meta-analysis Nephrol Dial Transplant (2014) 29: Vaughan Washco.
“Systemic Lupus Erythematosus” Renal features
Hypertension JNC VIII Guidelines.
Drugs for Hypertension
Dike Ojji Senior Lecturer
Volume 1: Chronic Kidney Disease Chapter 5: Acute Kidney Injury
Sympathetic stimulation of the kidney leads to the release of renin, with a resultant increase in the circulating levels of angiotensin II and aldosterone.
Volume 67, Pages S1-S7 (June 2005)
Congestive heart failure
Heart Failure Prognosis & Management
Acute and Chronic Renal Failure
Cardiorenal syndrome Domina Petric, MD.
Introduction: Alarming Statistics Causes of Death in Prevalent Dialysis Patients,
The pathophysiology of myocardial infarction-induced heart failure
Volume 2: End-Stage Renal Disease Chapter 4: Hospitalization
Hypertension: A Risk Factor For Stroke
The percentage of subjects with de novo development of renal function impairment (GFR
HYPERTENSIVE CRISES Mini-Lecture.
Diuretics, Kidney Diseases Urine R&M
Acute Kidney Injury in Patients With Cirrhosis: Perils and Promise
Cardiac Biomarkers: Key Takeaways for Use in Heart Failure and Acute Coronary Syndrome.
Volume 89, Issue 6, Pages (June 2016)
2018 Annual Data Report Volume 1: Chronic Kidney Disease
Expert Insights on Complex Clinical Cases of Edema
Therapeutic Strategies for Heart Failure in Cardiorenal Syndromes
Hepatorenal syndrome in cirrhosis: Pathogenesis and treatment
What is the relative risk reduction of ACEi’s/beta blockers for HFrEF?
Current Controversies and Advances in Hepatorenal Syndrome
Adjusted relative risk for developing end-stage renal disease (ESRD) associated with blood-pressure level BP level (mm Hg) Adjusted relative risk 95%
Volume 62, Issue 4, Pages (October 2002)
Michael R. Lattanzio, Matthew R. Weir  Kidney International 
Khalid AlHabib Professor of Cardiac Sciences Cardiology Consultant
Presentation transcript:

John Morris, MD Nephrology – BMH Memphis I have the following financial relationships with commercial interests to disclose: NONE Disclosure

Cardiorenal Syndrome No pump, no pee, no mystery. John T. Morris, III, M.D.

2004 Working Group- heart failure treatment limited by worsening renal function 2008 Working Group- 5 part classification scheme Type 1: Acute cardiorenal syndrome Type 2: Chronic cardiorenal syndrome Type 3: Acute renocardiac syndrome Type 4: Chronic renocardiac syndrome Type 5: Secondary cardiorenal syndrome Definition:

PRE-TEST Polling Questions

CASE #1: Match the clinical scenario with class of CRS A 26 yo AAF with active lupus nephritis presents with a creatinine of 2.4, albumin of 2.1, 3 plus pitting edema, UA with > 300 of protein and large blood, mild pulmonary edema on CXR, proBNP=3000, and troponin of 1.5 A.CRS I B.CRS II C.CRS III D.CRS IV E.CRS V 20

CASE #2: Match the clinical scenario with class of CRS 67 yo WM presents with abdominal pain and found to have 2 blood cultures with Gram positive cocci, a creatinine of 2.9, AST= 250, lactic acid of 4, and a troponin of 4.2 A.CRS I B.CRS II C.CRS III D.CRS IV E.CRS V 20

CASE #3: Match the clinical scenario with class of CRS 36 yo AA male with dilated CMP on home Milrinone presents with increased SOB and edema. He is admitted to the hospital and started on Lasix 80 mg IV q 8 hrs and 10 mg Zaroxolyn q day. His creatinine of admission was 0.9. His creatinine on hospital day 3 is 2.4 A.CRS I B.CRS II C.CRS III D.CRS IV E.CRS V 20

CASE #4: Match the clinical scenario with class of CRS 58 yo WF with ESRD on maintenance dialysis for 6 years poorly compliant with phosphate binders has an intact PTH of 490, phosphorus of 8.2, and and ECHO that revealed LVH presents to the ER after she began having chest pain while on dialysis. Initial troponin in ER minimally elevated A.CRS I B.CRS II C.CRS III D.CRS IV E.CRS V 20

CASE #5: Match the clinical scenario with class of CRS 26 yo WM was diagnosed 2015 with idiopathic dilated CMP initially treated with ACE, Betablocker, and diuretics has had progression of his disease and is now on continuous Milrinone. His creatinine was.9 to 1.1 for most of 2015 but has been 1.5 to 1.7 for the past several months. No protein in his UA A.CRS I B.CRS II C.CRS III D.CRS IV E.CRS V 20

 Of CKD in HF: about 30-60% -ADHERE database -Systemic review by Lichtman  Of AKI in HF: about 20-30%  POSH study Prevalence

Impaired kidney function in heart failure is defined as a reduction in GFR …duh!  Problems with creatinine  Production  Secretion  Problems estimating GFR  Acute vs. chronic kidney disease Diagnosis

 Impaired kidney function is diagnosed with a decrease in GFR-duh - Problems with creatinine, problems with estimating GFR

Glomerulus

 Neurohormonal adaptations - Sympathetic nervous system -RAAS -Vasopressin -Endothelin-1  Reduced renal perfusion - ESCAPE trial  Increased renal venous pressures -Human and animal studies have shown that increased abdominal pressure and/or elevated CVP can cause a reduction in GFR Pathophysiology

Sympathetic nervous system  activated due to decreased stroke volume and cardiac output  causes arterial vasoconstriction and increased myocardial contractility and heart rate Pathophysiology, con’t

RAAS

GFR Maintenance

Pathophysiology

Endothelin  potent vasoconstrictor  has been implicated in progression of renal failure and glomerular hypertrophy  causes hypertrophy of cardiac myocytes  stimulates and potentiates noradrenaline, angiotensin II, and aldosterone Pathophysiology

Reduced renal perfusion  ESCAPE trial- 433 patients with ADHF  no correlation between C.I. and either GFR or WRF for C.I above 1.5  Improving C.I. did not improve renal fx at discharge Pathophysiology

Increased renal venous pressure  Mullins study in patients with ADHF  40 % developed AKI. These patients had higher CVPs and admit and discharge  WRF less frequent in patients who achieved CVP less than 8  CVP was able to risk stratify for the development of WRF Pathophysiology

…Increased renal venous pressure (continued)  Incremental risk of WRF with higher categories of baseline CVP  75% of patients with CVP>24 developed WRF and mean baseline CVP higher (18 vs 12) in patients who had WRF…….linear relationship  2 strongest determinants for developing WRF were presence of CKD and increased CVP  Improved C.I. had no correlation with WRF Pathophysiology

…Increased renal venous pressure (continued) Mechanism  increased pressure transmitted back to renal vein causing increased renal interstitial pressure Pathophysiology

POST-TEST Polling Questions

CASE #1: Match the clinical scenario with class of CRS A 26 yo AAF with active lupus nephritis presents with a creatinine of 2.4, albumin of 2.1, 3 plus pitting edema, UA with > 300 of protein and large blood, mild pulmonary edema on CXR, proBNP=3000, and troponin of 1.5 A.CRS I B.CRS II C.CRS III D.CRS IV E.CRS V 20

CASE #2: Match the clinical scenario with class of CRS 67 yo WM presents with abdominal pain and found to have 2 blood cultures with Gram positive cocci, a creatinine of 2.9, AST= 250, lactic acid of 4, and a troponin of 4.2 A.CRS I B.CRS II C.CRS III D.CRS IV E.CRS V 20

CASE #3: Match the clinical scenario with class of CRS 36 yo AA male with dilated CMP on home Milrinone presents with increased SOB and edema. He is admitted to the hospital and started on Lasix 80 mg IV q 8 hrs and 10 mg Zaroxolyn q day. His creatinine of admission was 0.9. His creatinine on hospital day 3 is 2.4 A.CRS I B.CRS II C.CRS III D.CRS IV E.CRS V 20

CASE #4: Match the clinical scenario with class of CRS 58 yo WF with ESRD on maintenance dialysis for 6 years poorly compliant with phosphate binders has an intact PTH of 490, phosphorus of 8.2, and and ECHO that revealed LVH presents to the ER after she began having chest pain while on dialysis. Initial troponin in ER minimally elevated A.CRS I B.CRS II C.CRS III D.CRS IV E.CRS V 20

CASE #5: Match the clinical scenario with class of CRS 26 yo WM was diagnosed 2015 with idiopathic dilated CMP initially treated with ACE, Betablocker, and diuretics has had progression of his disease and is now on continuous Milrinone. His creatinine was.9 to 1.1 for most of 2015 but has been 1.5 to 1.7 for the past several months. No protein in his UA A.CRS I B.CRS II C.CRS III D.CRS IV E.CRS V 20